Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment.
BACKGROUND
Antiretroviral therapy in early HIV infection may enhance outcome and viral control may be better in acute versus recent infection 24 weeks after treatment interruption.


METHODS
A prospective trial of treatment stratified by acute versus recent HIV-1 infection. If HIV viral load <50 copies/ml after at least 52 weeks, treatment was interrupted. If viremia rebounded, treatment and interruption were repeated. The primary endpoint was maintaining viral load less than 5000 copies/ml for 24 weeks following treatment interruption.


RESULTS
Of the 121 patients enrolled at 15 sites, ninety-five percent were men, median age was 34 years; 69% were white. Median viral load was higher in acute HIV-1 infection (210 000 copies/ml) than recent HIV-1 infection (43 000 copies/ml). The 73 primary endpoint patients (28 acute HIV-1 infection, 45 recent HIV-1 infection) had significantly higher baseline CD4 T-cell counts (P = 0.044) and lower viral load (P = 0.016). The primary endpoint was achieved in 29 (40%) of the 73 and in 24% of the 121 enrolled overall. There was no significant outcome difference (P = 0.81) between the acute HIV-1 infection [43%, 95% confidence interval (CI) 24-63%] and recent HIV-1 infection (38%, 95% CI 24-53%) groups. Differences after longer follow-up can not be ascertained by this trial. Baseline viral load less than 100 000/ml 22/46 (48%) compared with more than 100 000/ml, 7/27 (26%) and higher baseline CD4 immune activation predicted success.


CONCLUSIONS
Forty percent of patients treated during acute HIV-1 infection or recent HIV-1 infection sustained a viral load less than 5000 copies/ml after 24 weeks of treatment interruption.
Volberding
Paul
P
University of California-San Francisco, 4150 Clement Street, San Francisco, CA 94121, USA. Paul.volberding@va.gov
Demeter
Lisa
L
Bosch
Ronald J
RJ
Aga
Evgenia
E
Pettinelli
Carla
C
Hirsch
Martin
M
Vogler
Mary
M
Martinez
Ana
A
Little
Susan
S
Connick
Elizabeth
E
D000208:Acute Disease; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D018791:CD4 Lymphocyte Count; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D016896:Treatment Outcome; D019562:Viral Load; D014766:Viremia / Q000188:drug therapy / Q000821:virology
D019380:Anti-HIV Agents; D012367:RNA, Viral
Nature. 2000 Sep 28;407(6803):523-6
11029005
AIDS. 2000 Jan 28;14(2):123-31
10708282
Arch Intern Med. 2003 May 26;163(10):1220-6
12767960
Clin Infect Dis. 2004 Feb 1;38(3):412-7
14727214
Blood. 2004 Aug 15;104(4):942-7
15117761
J Acquir Immune Defic Syndr. 2006 Jun;42(2):192-202
16688094
J Acquir Immune Defic Syndr. 2008 Jun 1;48(2):149-55
18360289
J Infect Dis. 2006 Sep 15;194(6):725-33
16941337
AIDS. 2008 Feb 19;22(4):439-46
18301056
Nature. 2005 Apr 28;434(7037):1093-7
15793563
N Engl J Med. 2006 Nov 30;355(22):2283-96
17135583
J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):140-47
18300365
Ann Intern Med. 1998 Apr 15;128(8):613-20
9537934
J Virol. 2003 Nov;77(21):11708-17
14557656
Science. 1996 May 24;272(5265):1167-70
8638160
AIDS. 1995 Jun;9(6):597-604
7662199
BMJ. 1989 Jul 15;299(6692):154-7
2569901
J Infect Dis. 2000 Mar;181(3):872-80
10720507
N Engl J Med. 2001 Mar 8;344(10):720-5
11236775
J Infect Dis. 2006 Sep 1;194(5):623-32
16897661
AIDS Res Hum Retroviruses. 2003 Mar;19(3):189-99
12689411
J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):445-8
17514014
PLoS Med. 2004 Dec;1(3):e64
15630469
PLoS Med. 2004 Nov;1(2):e36
15526059
JAMA. 1995 Aug 16;274(7):554-8
7629984
J Infect Dis. 2008 Mar 1;197(5):714-20
18260759
Clin Infect Dis. 2007 Aug 1;45(3):381-90
17599319